Lagosin is a polyene macrolide antibiotic for antifungal research
**Background**
Fungal infections pose a significant threat to both immunocompromised patients and agricultural productivity. Among the various fungal pathogens, Fusarium oxysporum is particularly notorious for causing vascular wilt in a wide range of plants, leading to substantial crop losses worldwide. The development of effective antifungal agents is often hindered by the emergence of drug resistance, necessitating the discovery of novel compounds with broad-spectrum activity and the ability to bypass existing resistance mechanisms. Polyene macrolides have long been recognized for their ability to disrupt fungal cell membranes, making them essential tools in combating resistant strains. In this context, we will introduce a polyene macrolide antibiotic – Lagosin.
**Definition**
Lagosin (also known as Fungichromin) is a polyene macrolide antibiotic that targets macrolide-related pathways to exert its effects. According to the Lagosin technical information, it possesses a molecular weight of 670.83 and a chemical formula of C35H58O12.
**In Vitro Studies**
The Lagosin description identifies this compound as a product of Streptomyces sp. WP-1, an endophyte derived from Pinus dabeshanensis. In terms of Lagosin In Vitro activity, research has demonstrated that the compound exhibits broad-spectrum antifungal properties. Specifically, it has shown significant antifungal activity against Fusarium oxysporum, a major plant pathogen. A key advantage of Lagosin is that it remains impervious to agent resistance, suggesting its potential as a robust alternative to traditional antifungal therapies. While specific IC50 values and time-course data for various cell lines were not provided in the primary source, the Lagosin biological activity is characterized by its potent ability to inhibit fungal growth. In conclusion, Lagosin is a polyene macrolide antibiotic with promising broad-spectrum antifungal activity.
Keywords
Lagosin, 6834-98-6, Fungichromin, Pentamycin, Cogomycin, Antibiotic, Fungal, antifungal, polyene, macrolide, antibiotic, resistance, Inhibitor, inhibitor, inhibit
References
**Background**
Exchange proteins directly activated by cAMP (EPAC) are a family of guanine nucleotide exchange factors that play a critical role in regulating a wide variety of intracellular processes. These proteins respond to the second messenger cAMP to modulate various signaling pathways, contributing to physiological functions across multiple organ systems. Given their involvement in diverse cellular responses, EPACs have become significant targets for pharmacological intervention in various research areas. Understanding the specific roles of EPAC1 and EPAC2 is essential for developing targeted therapies. In this context, we will introduce a potent and selective EPAC antagonist – ESI-08.
**Definition**
ESI-08 is a potent and selective EPAC antagonist that can completely inhibit the activity of both EPAC1 and EPAC2 with an IC50 value of 8.4 μM.
**In Vitro Studies**
According to the ESI-08 description, this compound selectively blocks cAMP-induced EPAC activation without inhibiting cAMP-mediated PKA activation. In terms of ESI-08 biological activity, in vitro studies demonstrated that ESI-08 at a concentration of 25 μM does not alter the activation of cAMP-induced type I and II PKA holoenzymes. This selectivity is highlighted by the fact that while ESI-08 maintains PKA activity, H89, a selective PKA inhibitor, completely blocks type I or II PKA activities. The ESI-08 formula is C20H23N3OS, with a molecular weight of 353.48. These findings indicate that ESI-08 is a highly specific tool for studying EPAC-mediated signaling pathways independently of the PKA pathway. In conclusion, ESI-08 is a potent and selective antagonist of EPAC1 and EPAC2.
Keywords
ESI-08, 301177-43-5, ESI08, ESI 08, Ras, EPAC, cAMP, EPAC1, EPAC2, exchange, proteins, Inhibitor, inhibitor, inhibit
References
**Background**
The serotonin (5-hydroxytryptamine, 5-HT) receptor family consists of several subtypes that play critical roles in regulating mood, cognition, and nociception. Among these, the 5-HT 1E and 5-HT 1F receptors are of particular interest due to their specific distribution in the mammalian brain and cerebral vasculature. Understanding the pharmacological profiles of these receptors is essential for developing targeted therapies for neurological disorders and pain management. Given the complexity of serotonergic signaling, the development of highly selective ligands is necessary to avoid off-target effects associated with other 5-HT and dopamine receptors. In this context, we will introduce a potent 5-HT 1E/1F receptor agonist – BRL 54443.
**Definition**
BRL 54443 is a potent 5-HT 1E/1F receptor agonist with high binding affinity, exhibiting Ki values of 1.1 nM for the 5-HT 1E receptor and 0.7 nM for the 5-HT 1F receptor.
**In Vitro and In Vivo Studies**
The BRL 54443 description highlights its exceptional selectivity, displaying more than 30-fold selectivity over other 5-HT and dopamine receptors. Regarding BRL 54443 in vitro activity, the compound shows low affinity for 5-HT 1A (63 nM), 5-HT 1B (126 nM), 5-HT 1D (63 nM), 5-HT 2A (1259 nM), 5-HT 2B (100 nM), and 5-HT 2C (316 nM), with negligible binding to 5-HT 6 and 5-HT 7 receptors (>10,000 nM). In DG membranes, BRL 54443 selectively stimulates 5-HT 1E receptors and potently inhibits forskolin-dependent cAMP production with an IC50 of 14 nM. Additionally, it has been shown to induce contraction with a -log EC50 of 6.52.
Evaluation of BRL 54443 In Vivo has demonstrated its potential in antinociception research. In rat models, the peripheral administration of BRL 54443 (3-300 μg/paw) to the ipsilateral side significantly reduced formalin-induced flinching, whereas contralateral administration did not produce the same effect. These findings suggest a peripheral role for 5-HT 1E/1F receptors in modulating pain responses. For researchers seeking detailed BRL 54443 technical information, these results underscore the compound’s utility as a selective tool for studying serotonergic pathways. In conclusion, BRL 54443 is a highly selective 5-HT 1E/1F receptor agonist suitable for pharmacological research in nociception and signal transduction.
Keywords
BRL 54443, 57477-39-1, BRL54443, BRL-54443, 5-HT Receptor, Serotonin Receptor, 5-hydroxytryptamine Receptor, Inhibitor, inhibitor, inhibit
References
[1] Klein MT, et al. Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-867.
[2] McKune CM, et al. Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther. 2001 Apr;297(1):88-95.
[3] Klein MT, et al. Distribution of 5-ht(1E) receptors in the mammalian brain and cerebral vasculature: an immunohistochemical and pharmacological study. Br J Pharmacol. 2012 Jun;166(4):1290-302.
[4] Granados-Soto V, et al. The role of peripheral 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F serotonergic receptors in the reduction of nociception in rats. Neuroscience. 2010 Jan 20;165(2):561-8.
**Background**
The NLRP3 inflammasome plays a pivotal role in the innate immune response, where its activation leads to the maturation and release of pro-inflammatory cytokines such as IL-1β and IL-18. Dysregulation of the NLRP3 pathway is implicated in various inflammatory conditions, including sepsis, peritonitis, and acute lung injury, as well as the progression of certain malignancies. Consequently, targeting the NLRP3 inflammasome has become a significant strategy for developing therapeutic interventions for these diseases. In the context of oncology, inhibiting inflammatory signaling and inducing apoptosis are critical for treating hepatocellular carcinoma. Therefore, we will introduce a selective, orally active NLRP3 inhibitor – Tabersonine.
**Definition**
Tabersonine is an indole alkaloid that acts as a selective NLRP3 inhibitor, demonstrating an IC50 of 0.71 μM for inhibiting NLRP3-mediated IL-1β production in BMDM cells.
**Mechanism of Action**
According to the Tabersonine description, this compound directly binds to the NACHT domain of NLRP3, which inhibits its ATPase activity and oligomerization. This mechanism blocks the formation of ASC spots and the activation of caspase-1, thereby reducing the release of IL-1β. Furthermore, Tabersonine inhibits the K63-linked ubiquitination of TRAF6, which subsequently blocks the NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. In the context of Tabersonine Cancer research, the compound induces apoptosis in liver cancer cells via mitochondrial and death receptor pathways by reducing mitochondrial membrane potential and promoting cytochrome c release.
**In Vitro and In Vivo Studies**
Extensive Tabersonine in vitro studies have demonstrated its potent biological activity. In human liver cancer cells (SMMC-7721, HepG2), Tabersonine (0.78-25 μM; 24 h) inhibited cell viability, with a stronger effect on tumor cells than on normal HL-7702 cells. Specifically, in SMMC-7721 cells, Tabersonine (6.25-25 μM; 24 h) induced apoptosis by upregulating Bax, cleaved-caspase-3, and cleaved-PARP while downregulating Bcl-2. Additionally, concentrations of 12.5-25 μM arrested the cell cycle at the G0/G1 phase via downregulation of CDK4 and Cyclin D1.
Tabersonine in vivo data further support its therapeutic potential. In mouse models of LPS-induced acute lung injury, Tabersonine (10-40 mg/kg; i.p.; daily for 30 days) reduced lung tissue damage, neutrophil infiltration, and levels of TNF-α, IL-6, and IL-1β. In a nude mouse HepG2 liver cancer xenograft model, oral administration of Tabersonine (25, 50 mg/kg; daily for 3 weeks) significantly inhibited tumor growth and promoted apoptosis. Moreover, in E. coli-induced sepsis models, Tabersonine (10 mg/kg; gavage; 3 times daily) increased the 48-hour survival rate to 60%. In conclusion, Tabersonine is a potent NLRP3 inhibitor with significant potential for treating inflammatory diseases and liver cancer.
Keywords
Tabersonine, 4429-63-4, Akt, Interleukin Related, NF-κB, p38 MAPK, CDK, NOD-like Receptor (NLR), Caspase, Apoptosis, Cytochrome P450, PI3K, PKB, Protein kinase B, IL
References
[1] Zhang D, et al. Tabersonine attenuates lipopolysaccharide-induced acute lung injury via suppressing TRAF6 ubiquitination. Biochem Pharmacol. 2018 Aug;154:183-192.
[2] Li X, et al. Tabersonine Induces the Apoptosis of Human Hepatocellular Carcinoma In vitro and In vivo. Anticancer Agents Med Chem. 2024;24(10):764-772.
[3] Xu HW, et al. Tabersonine, a natural NLRP3 inhibitor, suppresses inflammasome activation in macrophages and attenuate NLRP3-driven diseases in mice. Acta Pharmacol Sin. 2023 Jun;44(6):1252-1261.
**Background**
Endometriosis, uterine fibroids, and adenomyosis are common gynecological disorders characterized by the growth of endometrial-like tissue or benign tumors, often driven by the hypothalamic-pituitary-gonadal (HPG) axis. The gonadotropin-releasing hormone (GnRH) receptor plays a pivotal role in regulating the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn control the production of sex steroids. By antagonizing the GnRH receptor, it is possible to suppress the HPG axis and reduce the hormonal stimulation that fuels these estrogen-dependent conditions. Consequently, developing potent, non-peptide antagonists that can be administered orally is a significant goal for improving patient outcomes and research models. In this context, we will introduce a potent GnRH antagonist – Linzagolix.
**Definition**
Linzagolix (also known as KLH-2109 or OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. According to the Linzagolix description, this compound is designed to suppress the HPG axis to treat hormone-dependent gynecological and urological conditions.
**In Vivo Studies**
The Linzagolix biological activity has been demonstrated across several animal models to validate its efficacy in suppressing gonadal function. In vivo studies using an endometriosis model rat showed that administration of Linzagolix at a dosage of 50 mg/kg resulted in a significant reduction in cyst volume. Furthermore, research involving male rats and dogs, including those with benign prostatic hyperplasia (BPH) models, indicated that Linzagolix reduces serum luteinizing hormone and testosterone levels. These findings suggest that the compound effectively inhibits the release of gonadotropins, thereby lowering the systemic levels of sex steroids. For researchers seeking detailed Linzagolix technical information regarding its molecular weight of 508.42 and its specific chemical structure, the compound provides a robust tool for studying the suppression of the HPG axis. In conclusion, Linzagolix is a potent, orally active non-peptide GnRH antagonist that holds promise for the research of endometriosis, uterine fibroids, and adenomyosis.
Keywords
Linzagolix, 935283-04-8, KLH-2109, OBE-2109, KLH2109, KLH 2109, OBE2109, OBE 2109, GnRH Receptor, Gonadotropin releasing hormone receptor, GNRHR, uterine fibroids, endometriosis, adenomyosis
References
[1] Susan Dababou, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Sep;30(9):903-911.
[2] Motohiro Tezuka, et al. Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats. Clin Exp Pharmacol Physiol. 2023 Jul;50(7):610-617.
[3] Motohiro Tezuka, et al. Suppression of hypothalamic-pituitary-gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models. Clin Exp Pharmacol Physiol. 2023 Nov;50(11):914-923.